Description
Introduction
Companies seeking success in the depression market must react to the challenges posed by generic selective serotonin reuptake inhibitors (SSRIs). Complementing traditional antidepressants with novel modes of action in the adjunctive market will be an important point of entry, although demonstrating efficacy in patients with treatment-resistant depression is a sizable hurdle to overcome.
Features And Benefits
• In-depth discussion of brand lifecycle and portfolio management strategies of key companies involved in the depression market.
• Assess trends in corporate strategies of companies active in the depression arena and understand the impact of key recent licensing deals.
• Identify the leading companies involved in depression and how their franchises have performed over 2002-10.
• Learn how companies can respond to future opportunities and challenges in the field.
Highlights
While GlaxoSmithKline is walking away from depression research, other companies are responding to the challenges posed by generic SSRIs by focusing on treatment-resistant patients. As physicians are willing to prescribe concomitant depression therapies, developers are trialing candidates to augment traditional antidepressants at second line.
Pfizer is ceding ground to rivals such as Forest and Eli Lilly, as generic venlafaxine takes hold and Pristiq underperforms. Pfizer’s under-representation in the pipeline suggests that the company is moving away from depression research, rather than innovating and remaining at the forefront of the market.
Forest is a key player due to the company’s marketing clout and ability to spot licensing opportunities. Its future presence should be sustained by ongoing deal-making activities. Lundbeck also sees growth potential in the depression market, evident by its commitment to the development of novel antidepressants in collaboration with Takeda.
Your Key Questions Answered
• How successful are the portfolio management strategies most widely used in the depression market?
• How can emerging trends in the depression market be exploited by leading companies to guide strategic decisions?
• What can Pfizer’s depression portfolio realistically achieve following Effexor’s loss of market exclusivity?
• What are the implications of Forest’s acquisition of Clinical Data to its outlook?
• How can Lundbeck ensure longevity in the depression market beyond the patent expiry of Cipralex?
Table of Contents
Executive Summary
Strategic scoping and focus
Datamonitor key findings
OVERVIEW
Catalyst
Summary
COMPANY STRATEGIES
Strategic overview
Trends in corporate strategy
Targeting treatment-resistant depression with add-on therapies
Recent shifts in corporate strategy
Strategic refocusing at GlaxoSmithKline has resulted in a big player walking away from depression
Recent strategic partnerships/deals
Big Pharma seeks to partner with local players to expand geographical reach of mature brands
Forest’s acquisition of Clinical Data was the only notable M&A activity
PFIZER
Corporate strategy
Pfizer leaps to the top spot in depression largely due to its takeover of Wyeth
Effexor franchise has reached the end of its lifecycle, although Pfizer is attempting to prolong market share with Pristiq
Pristiq will be unable to maintain Pfizer’s antidepressant franchise revenues
Pfizer’s pipeline suggests that the company is moving away from depression
Depression portfolio assessment
Mature brands define Pfizer’s involvement in depression
SWOT analysis for Pfizer’s depression portfolio
FOREST LABORATORIES
Corporate strategy
In-licensing from Lundbeck created Forest’s antidepressant franchise
Acquisition of Clinical Data is a strong signal of Forest’s intention to stay in the depression market
Further collaborations may widen Forest’s future depression offerings
Depression portfolio assessment
Long-term future in depression ensured through in-licensing and acquisitions
SWOT analysis for Forest’s depression portfolio
LUNDBECK
Corporate strategy
Antidepressant franchise has shaped Lundbeck’s recent history
Lundbeck has been unable to match its commercial partner’s success
Mixed results thus far from Lundbeck’s collaboration with Takeda to develop a portfolio of novel antidepressant products
Depression portfolio assessment
High expectation rests with novel candidates to succeed Cipralex
SWOT analysis for Lundbeck’s depression portfolio
PORTFOLIO REVIEW OF OTHER LEADING COMPANIES
AstraZeneca
Pipeline is targeted against the unmet needs in depression, building on Seroquel XR’s initial success
Otsuka
Prolonging share of depression market with latest antipsychotic
Eli Lilly
Lilly maintains interest in the depression market
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
Appendix
PharmaVitae Explorer database
Contributing experts
Conferences attended
Report methodology
